ATR kinase inhibitors induce mitochondrial fission in CD8 + T cells and impair immune memory in vivo
Preprint
Abstract
The DNA damage response kinase ATR restrains CDK1 activity during S and G2 phases of the cell cycle, confining CDK1-driven processes to mitosis. ATR kinase inhibitors were originally developed to potentiate chemotherapy-induced DNA damage at stalled replication forks and to disrupt DNA damage-induced cell cycle checkpoints. Recent evidence, however, reveals that these inhibitors also disrupt cell cycle organization in cells that have not sustained any DNA damage. We show that ATR kinase inhibitors potently trigger unscheduled mitochondrial fission, causing loss of mitochondrial mass in actively dividing CD8 + T cells that persists in memory CD8 + T cells. Moreover, ATR inhibition during the peak of CD8 + T cell expansion in a mouse model of LCMV Armstrong infection impairs the formation of immune memory. These findings carry significant clinical implications. ATR kinase inhibitors are currently being evaluated in clinical trials in combination with chemotherapy, radiation, and immune checkpoint inhibitors in patients where anti-tumor immune responses are recognized as a determinant of durable response. Our results identify an unexpected consequence of ATR inhibition that disrupts cellular metabolism with broad implications for both preclinical research and clinical application.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI171483)
- National Institute of Allergy and Infectious Diseases (R01AI166598)
- Henry M. Jackson Foundation (HU0001-23-2-0038)
This publication has 80 references indexed in Scilit:
- Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)Cancer Chemotherapy and Pharmacology, 2025
- Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expressionCell Reports, 2022
- Memory T cells: strategies for optimizing tumor immunotherapyProtein & Cell, 2020
- Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor GrowthCell Reports, 2019
- Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon Metabolism for T Cell ActivationCell Metabolism, 2016
- Mitochondrial Dynamics Controls T Cell Fate through Metabolic ProgrammingCell, 2016
- PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative StressCancer Cell, 2013
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA RepairCell, 2012
- Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunityCancer Immunology, Immunotherapy, 2008
- Bax/Bak-Dependent Release of DDP/TIMM8a Promotes Drp1-Mediated Mitochondrial Fission and Mitoptosis during Programmed Cell DeathCurrent Biology, 2005